Registration was successful!
Please follow the link from the email sent to

Doctoring DNA: US Approves Cancer-Fighting Human Genetic Experiments

Subscribe
As a result of upcoming genetic trials, researchers may develop new ways to successfully treat different types of cancer and decrease mortality rates related to the disease, according to an article in the journal Science.

В вирусологической лаборатории Центра по профилактике и борьбе со СПИДом и инфекционными заболеваниями - Sputnik International
Genetically-Engineered HIV Cure May Come Within Years
The Recombinant DNA Advisory Committee (RAC) at the US National Institutes of Health has approved the application filed by a group of scientists from the University of Pennsylvania to carry out experiments involving the genetic modification of humans in an attempt to find new ways of treating cancer, Science reported.

The application has successfully undergone all safety regulations, although traditionally the advisory board has rejected such testing on humans due to safety concerns and ethics issues. However, this time the experiment has a concrete chance of yielding a real breakthrough in the field of medicine as researchers might develop a totally new approach to cancer, enabling successful treatment.

"It's an important new approach. We're going to learn a lot from this. And hopefully it will form the basis of new types of therapy," the journal cited clinical oncologist Michael Atkins of Georgetown University in Washington, DC as saying.

During their experiment, the research team is planning to use the red-hot gene-editing tool CRISPR to try to improve human immune cells that will allow the body to effectively combat cancer. CRISPR is expected to modify three different genome sites at once, a complicated procedure which has not been easy to carry out until now.

"For the CRISPR trial, a UPenn-led team wants to remove T cells from patients and use a harmless virus to give the cells a receptor for NY-ESO-1, a protein that is often present on certain tumors but not on most healthy cells. The modified T cells are then re-infused back into a patient and, if all goes well, attack the person's NY-ESO-1-displaying tumors," the journal wrote.

The experiments are expected to last for two years, and will be attended by 18 volunteers with various types of cancer: sarcoma, melanoma and myeloma. The genetic research will be carried out in three research centers: the University of Pennsylvania, the University of Houston and the University of California in San Francisco.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала